Avenue therapeutics, inc. (ATXI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating expenses:
Research and development

12,650

22,194

21,054

21,136

18,498

17,696

19,099

19,311

16,004

6,698

2,743

926

900

1,331

0

0

0

General and administrative

2,529

3,071

3,839

4,042

4,253

4,120

3,837

3,865

4,235

3,620

2,820

2,172

1,092

997

0

0

0

Loss from operations

-16,179

-26,265

-24,893

-25,178

-22,751

-21,816

-24,039

-24,279

-21,342

-11,421

-5,612

-3,147

-2,041

-2,377

0

0

0

Interest income

298

357

306

238

136

93

167

160

136

88

0

0

0

-

0

-

-

Interest expense

-

-

-

-

-

-

-

-

-

294

453

436

430

420

0

0

0

Interest expense - related party

-

-

-

-

-

-

-

-

-

81

141

194

220

192

0

0

0

Change in fair value of convertible notes payable

-

-

-

-

-

-

-

-

-

99

10

10

-85

0

0

0

0

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

451

620

639

185

188

0

0

0

Net Loss

-15,881

-25,908

-24,412

-24,765

-22,440

-21,548

-23,872

-24,225

-21,974

-12,258

-6,830

-4,426

-2,791

-3,177

0

0

0

Net loss per common share outstanding, basic and diluted

-0.08

-0.26

-0.14

-0.43

-0.82

-0.37

-0.25

-0.45

-1.03

-0.63

-0.30

-0.70

-0.22

-1.45

0.19

0.28

-0.13

Weighted average number of common shares outstanding, basic and diluted

16,474

16,452

16,376

16,314

13,742

10,309

10,295

10,251

10,099

10,084

9,972

3,459

3,022

-2,503

2,848

2,785

8,310